Literature DB >> 10637475

Chemosensitivity of B cell chronic lymphocytic leukemia and correlated expression of proteins regulating apoptosis, cell cycle and DNA repair.

A Klein1, O Miera, O Bauer, S Golfier, F Schriever.   

Abstract

B cell chronic lymphocytic leukemia (B-CLL) cannot be cured with conventional chemotherapy. This clinical enigma appears to be at least partially due to the fact that B-CLL cells are resistant to programmed cell death (apoptosis) and that they are arrested in G0/G1 phase of the cell cycle. The reasons for the dysregulation of these two key cellular events in B-CLL are unclear. The present study aimed at determining correlations between the expression levels of proteins regulating apoptosis, cell cycle and DNA repair in B-CLL cells and normal B cells. In addition, the differential sensitivity of B-CLL cells to drug-induced apoptosis was quantified. We show that in B-CLL cells levels of the death-suppressor Bcl-2 correlated positively with those of the pro-apoptotic protein Bax and of the cyclin-dependent kinase (cdk) inhibitor p27Kip1. In B-CLL cells levels of the anti-apoptotic Bcl-xL showed a positive correlation with levels of the 80 kDa regulatory component (Ku80) of the DNA-dependent protein kinase that is involved in DNA double-stranded break repair. These correlations were not detected in normal B cells. The sensitivity of leukemic cells to FLUD but not to ADM, CPM or to DEX was reduced in pre-treated patients. These data support the hypothesis that in B-CLL cells death-modulators and molecules modulating cell cycle and DNA repair are regulated in a coordinated manner. Leukemia (2000) 14, 40-46.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10637475     DOI: 10.1038/sj.leu.2401636

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  9 in total

Review 1.  New directions in the diagnosis and treatment of chronic lymphocytic leukaemia.

Authors:  Folke Schriever; Dieter Huhn
Journal:  Drugs       Date:  2003       Impact factor: 9.546

2.  Analysis of CD23 antigen expression in B-chronic lymphocytic leukaemia and its correlation with clinical parameters.

Authors:  Vladimir Jurisic; Natasa Colovic; Nada Kraguljac; Henry Dushan Atkinson; Milica Colovic
Journal:  Med Oncol       Date:  2008-01-09       Impact factor: 3.064

Review 3.  Therapy of chronic lymphocytic leukaemia with purine nucleoside analogues: facts and controversies.

Authors:  Tadeusz Robak
Journal:  Drugs Aging       Date:  2005       Impact factor: 3.923

4.  Overexpression of nucleolin in chronic lymphocytic leukemia cells induces stabilization of bcl2 mRNA.

Authors:  Yoko Otake; Sridharan Soundararajan; Tapas K Sengupta; Ebenezer A Kio; James C Smith; Mauricio Pineda-Roman; Robert K Stuart; Eleanor K Spicer; Daniel J Fernandes
Journal:  Blood       Date:  2007-04-01       Impact factor: 22.113

Review 5.  The potential of venetoclax (ABT-199) in chronic lymphocytic leukemia.

Authors:  Gilad Itchaki; Jennifer R Brown
Journal:  Ther Adv Hematol       Date:  2016-07-08

6.  Vesicular stomatitis virus oncolysis of T lymphocytes requires cell cycle entry and translation initiation.

Authors:  Stephanie Oliere; Meztli Arguello; Thibault Mesplede; Vanessa Tumilasci; Peyman Nakhaei; David Stojdl; Nahum Sonenberg; John Bell; John Hiscott
Journal:  J Virol       Date:  2008-04-16       Impact factor: 5.103

7.  The DNA repair complex Ku70/86 modulates Apaf1 expression upon DNA damage.

Authors:  D De Zio; M Bordi; E Tino; C Lanzuolo; E Ferraro; E Mora; F Ciccosanti; G M Fimia; V Orlando; F Cecconi
Journal:  Cell Death Differ       Date:  2010-10-22       Impact factor: 15.828

8.  Evaluation of Caspase-9b and PP2Acα2 as potential biomarkers for chronic lymphocytic leukemia.

Authors:  Leticia Domínguez-Berrocal; Xiguang Zhang; Jean Marc Zini; Jesús Fominaya; Angelita Rebollo; Jerónimo Bravo
Journal:  Biomark Res       Date:  2016-05-04

9.  Ku protein levels, localization and association to replication origins in different stages of breast tumor progression.

Authors:  Khalil Abdelbaqi; Domenic Di Paola; Emmanouil Rampakakis; Maria Zannis-Hadjopoulos
Journal:  J Cancer       Date:  2013-05-26       Impact factor: 4.207

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.